HK Stock Market Move | ABISKOB(02256) rose by more than 4% against the market, as the clinical approval related to ipaglotinib, and the data for pimetinib is attractive.

ABBISKO-B (02256) rose more than 4% against the market trend, with a 4.48% increase at the time of writing, trading at 4.66 Hong Kong dollars, with a turnover of 1104.74 million Hong Kong dollars. On the news front, Heyu recently announced that its independently developed highly selective small molecule FGFR4 inhibitor, Ipageritini (ABSK011), has been approved by the China National Drug Administration Drug Evaluation Center to conduct registration clinical studies for the treatment of Hepatocellular Carcinoma (HCC). In addition, the company recently released preliminary phase II data for Pimetinib in cGvHD. CITIC Securities stated that Pimetinib has a promising relief rate for cGvHD and has the potential for further improvement. Guotai Junan International stated that Heyu's founder team, Dr. Xu Yaochang, Dr. Yu Hongping, and Dr. Chen Zhuo, have an entrepreneurial spirit in innovative drug development. The company has strong competitiveness in small molecule drugs, and the successful approval of Ipageritini for the treatment of liver cancer reflects the company's high efficiency in innovative drug research and development. The company is expected to achieve a breakthrough in the field of oncology, with a wide market space and currently undervalued. The company's long-term development prospects are promising.